Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of pioneering biological therapeutics for the treatment of rare disorders. With a significant focus on novel treatment methodologies, Capricor leverages an extensive body of scientific research to innovate in the biotech sector.
The company's lead candidate, CAP-1002, is an “off-the-shelf” cardiac cell therapy designed for the treatment of Duchenne Muscular Dystrophy (DMD). CAP-1002 is composed of allogeneic cardiosphere-derived cells (CDCs), a unique cell population known for its potent immunomodulatory properties. These properties help in altering the immune system's activity to stimulate cellular regeneration. The efficacy and safety of CDCs are well-documented, with over 100 peer-reviewed scientific publications and administration to around 140 human subjects across several clinical trials.
Capricor's development pipeline also includes CDC-Exosomes (CAP-2003) and an Exosome-mRNA vaccine. These innovative platforms underline the company's commitment to expanding its therapeutic reach beyond DMD, addressing multiple medical conditions.
The company has recently shared positive updates, such as the 24-month results from the HOPE-2 Open Label Extension Study of CAP-1002 for DMD, highlighting sustained benefits and safety. Additionally, Capricor has ongoing programs addressing the COVID-19 pandemic and exploring new frontiers in exosome-based therapies.
Financially, Capricor continues to achieve crucial milestones, effectively managing its resources to advance its clinical programs. Recent operational highlights include strategic corporate updates and anticipated milestones for the CAP-1002 Duchenne Muscular Dystrophy Program and Exosome Program. The company actively engages with the scientific community through presentations and conference calls, emphasizing transparency and keeping stakeholders informed.
Capricor’s partnerships and collaborations further strengthen its research and development efforts, paving the way for groundbreaking advancements in treating rare and debilitating diseases. The company remains a significant player in the biotechnology sector, committed to transforming innovative research into tangible, life-changing therapies.
Capricor Therapeutics announced promising results from its StealthX™ exosome platform, demonstrating the ability to induce long-lasting immunity against multiple SARS-CoV-2 proteins. The preclinical study published in bioRxiv highlights the potential of two vaccine candidates-STX-S and STX-N-to generate a strong immune response with minimal protein dosage, eliminating the need for adjuvants. This development supports the viability of StealthX™ as a versatile vaccine platform, enhancing prospects for future therapies against infectious diseases.
Capricor Therapeutics (NASDAQ: CAPR) reported progress in the HOPE-3 Phase 3 clinical trial of CAP-1002 for Duchenne Muscular Dystrophy (DMD), alongside significant one-year results from the HOPE-2 study showing improved muscle function. The third-quarter financials reveal revenues of $1.6 million, driven by a $30 million payment from Nippon Shinyaku, while net loss increased to $6.4 million. With cash reserves of $46.6 million, Capricor anticipates funding through Q2 2024. The company is also advancing its StealthX™ platform for COVID-19 vaccines and exploring global partnerships.
Capricor Therapeutics (NASDAQ: CAPR) will announce its third-quarter financial results for the period ending September 30, 2022, after market close on November 10, 2022. Following the release, management will hold a webcast and conference call at 4:30 p.m. ET. The company is focused on developing innovative cell and exosome-based therapeutics for various diseases, with its lead candidate, CAP-1002, in late-stage clinical development for Duchenne muscular dystrophy.
Capricor Therapeutics (NASDAQ: CAPR) announced the presentation of one-year safety and efficacy results from its HOPE-2 open-label extension study for CAP-1002, targeting Duchenne muscular dystrophy (DMD). The findings will be showcased during the World Muscle Society Congress from October 11-15, 2022, in Halifax, Canada. Linda Marbán, CEO, expressed pride in sharing this data to enhance awareness of DMD. The study's poster presentation is scheduled for October 14, 2022, highlighting a new treatment approach for muscle pathogenesis.
Capricor Therapeutics (NASDAQ: CAPR) announced its participation in upcoming investor conferences in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, from 1:30 - 2:00 p.m. ET, which includes a presentation and one-on-one meetings. Additionally, Capricor will be featured in a panel at the Cantor Fitzgerald Cell & Genetics Medicines Conference on September 15, 2022. The events will be accessible via webcast, with presentations archived on Capricor's website.
Capricor Therapeutics (NASDAQ: CAPR) has initiated the pivotal Phase 3 HOPE-3 clinical trial for CAP-1002, targeting patients with late-stage Duchenne Muscular Dystrophy (DMD). Positive results from the HOPE-2 open label extension study showcase significant improvements in muscle function. The company is pursuing FDA discussions for CAP-1002's development. Financially, Capricor reported a net loss of $7.1 million for Q2 2022, but has sufficient cash to fund operations into Q2 2024. A partnership with Nippon Shinyaku supports HOPE-3 with a $30 million upfront payment.
Capricor Therapeutics (NASDAQ: CAPR) announces it will release its financial results for the second quarter ended June 30, 2022, after market close on August 10, 2022. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics, particularly its lead candidate, CAP-1002, for treating Duchenne muscular dystrophy. More details can be found at capricor.com.
Capricor Therapeutics (NASDAQ: CAPR) has announced the start of patient dosing in the HOPE-3 Phase 3 clinical trial for CAP-1002, a cell therapy aimed at treating late-stage Duchenne muscular dystrophy (DMD). This randomized, double-blind, placebo-controlled study is set to enroll about 70 patients in the U.S. Positive results from the earlier HOPE-2 trial suggested CAP-1002 could slow the loss of upper limb function by up to 70%. A partnership with Nippon Shinyaku Co., Ltd. will support this trial's funding, while CAP-1002 holds regulatory designations that may facilitate its path to market approval.
Capricor Therapeutics (NASDAQ: CAPR) announces positive one-year results from its HOPE-2 open label extension study for CAP-1002 in non-ambulant patients with Duchenne muscular dystrophy (DMD). The study met its primary endpoint, showing significant improvements in the Performance of the Upper Limb (PUL 2.0) scale (p=0.02). CAP-1002 was administered to 20 original patients, 12 of whom completed the year-long follow-up. The FDA has granted CAP-1002 RMAT and Orphan Drug Designation. Capricor plans to present these findings to the FDA while currently conducting a Phase 3 trial (HOPE-3).
Capricor Therapeutics (NASDAQ: CAPR) announced it will present one-year results from its HOPE-2 study on June 25, 2022, at the PPMD Annual Conference in Scottsdale, Arizona. Dr. Linda Marbán will lead a late-breaking session at 5:05 p.m. MT, sharing safety and efficacy results for their lead asset CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The conference, the largest international event for DMD research, will occur from June 22-26, 2022, with an option for virtual attendance.
FAQ
What is the current stock price of Capricor Therapeutics (CAPR)?
What is the market cap of Capricor Therapeutics (CAPR)?
What does Capricor Therapeutics Inc. specialize in?
What is CAP-1002?
What are cardiosphere-derived cells (CDCs)?
What recent achievements has Capricor announced?
How many human subjects have received CAP-1002?
What other programs does Capricor have in its pipeline?
Does Capricor have a focus on COVID-19 treatments?
What financial updates has Capricor recently provided?
How does Capricor engage with the scientific community?
What makes Capricor a significant player in the biotech sector?
